ArticleBreast cancer research : BCR2022

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Leonie Ratz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.